Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment

類似資料

• CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients
  著者:: Frerichs, Kristine A., 等
  出版事項: (2019)
• Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients
  著者:: Frerichs, Kristine A., 等
  出版事項: (2020)
• T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
  著者:: Verkleij, Christie P.M., 等
  出版事項: (2020)
• Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma
  著者:: Zajec, Marina, 等
  出版事項: (2020)
• Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
  著者:: Frerichs, Kristine A., 等
  出版事項: (2021)